evaluate novo nordisk on glp-1 agonists Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Overview of GLP-1s

This study adheres to the reporting guidelines outlined within the 'Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement

Wyse was named to King Charles IIIs New Year Honours List for 2024

Semaglutide Brand-Name Options: Wegovy (Weight Loss Approval): Approved For: Chronic weight management Dosing: Once-weekly injection, up to 2.4 mg Cost: $1,349/month without insurance Availability: Periodic shortages Ozempic (Diabetes Approval): Approved For: Type 2 diabetes Dosing: Once-weekly injection, up to 2.0 mg Cost: $969/month without insurance Often prescribed off-label for weight loss Compounded Semaglutide: The Most Affordable Option: Cost: $199-$599/month (TrimRx: $199/month) Same active ingredient as Wegovy/Ozempic Available through telehealth platforms Better availability than brand-name options Cost Comparison: Tirzepatide vs Semaglutide: When to Choose Semaglutide Over Tirzepatide: Budget is Primary Concern: Compounded semaglutide at $199/month costs $150/month less than compounded tirzepatide ($349/month)

A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity

JAMA Intern Med 173:534539 Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies